## **Depression – Antidepressants, Other**

Point-of-Sale (POS) edits are safety limitations that are automatically verified through computer programming at the time that a prescription claim is submitted at the pharmacy. These edits can be applied to *any* medication, whether or not it is listed in the Preferred Drug List / Non-Preferred Drug List (PDL/NPDL). The first section of this document is organized to follow the order of the therapeutic classes in the PDL/NPDL and explains the POS edits for those medications.

### **POS Abbreviations**

AL – Age Limit	DS – Maximum Days' Supply Allowed	<b>PU</b> – Prior Use of Other Medication is Required
<b>BH</b> – Behavioral Health Clinical Authorization for Children Younger than 7 Years of Age	<b>DT</b> – Duration of Therapy Limit	<b>QL</b> – Quantity Limit
<b>BY</b> – Diagnosis Codes Bypass Some Requirements	<b>DX</b> – Diagnosis Code Requirement	RX – Specific Prescription Requirement
<b>CL</b> – Additional Clinical Information is Required	<b>ER</b> – Early Refill	<b>TD</b> – Therapeutic Duplication
<b>CU</b> – Concurrent Use with Other Medication is Restricted	MD – Maximum Dose Limit	<b>YQ</b> – Yearly Quantity Limit
<b>DD</b> – Drug-Drug Interaction	MME – Maximum Morphine Milligram Equivalent is Restricted	

## **Depression – Antidepressants, Other**

### **POS Edits**

BH – Additional behavioral-health related clinical information (trial of behavioral therapy, etc.) is required for all agents (except, Spravato®, Zulresso<sup>TM</sup> and Zurzuvae<sup>TM</sup>) when requested for recipients who are younger than 7 years of age.

 $\textbf{CL}-\textbf{Additional clinical information (age, diagnosis, etc.) is required for brexanolone (Zulresso^{TM}), esketamine (Spravato®) and zuranolone (Zurzuvae^{TM}).}$ 

QL – Some agents have quantity limits as listed in the chart to the right.

Generic (Brand Example)	Quantity Limit
Zuranolone (Zurzuvae <sup>TM</sup> ) 20 mg	28 capsules per 14 days
Zuranolone (Zurzuvae <sup>TM</sup> ) 25 mg	28 capsules per 14 days
Zuranolone (Zurzuvae <sup>TM</sup> ) 30 mg	14 capsules per 14 days

Revision / Date	Implementation Date
Created POS Document	February 2020

# ${\bf Depression-Antidepressants, Other}$

Modified to apply new age requirement for behavioral health clinical authorization / September 2020	January 2021
Policy clarification / July 2022	October 2022
Policy clarification / February 2023	April 2023
Formatting changes / August 2023	October 2023
Added Zurzuvae <sup>TM</sup> / May 2024	July 2024
Added QL for Zurzuvae <sup>TM</sup> / May 2024	October 2024